Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Radium-223 in men with bone mCRPC

Daniel George, MD, of the Duke University Cancer Center, Durham, NC, discusses the use of Radium-223 in the treatment of bone metastatic castrate resistant prostate cancer at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.